Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Redx reshuffles board and clarifies new strategy ahead of rejoining junior market

“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”
test tubes in a laboratory
Redx is focusing on its two lead cancer and fibrosis candidates

Big changes are underway at Redx Pharma Plc (LON:REDX) as the drug discovery group rejoins the junior market today (Monday).

The company had been in administration since May after a £2mln loan from Liverpool City Council made to its subsidiary, Redx Oncology, fell due.

READ: Redx shares suspended as Liverpoool City Council calls in loan

Over summer the administrators, FRP Advisory, sold Redx’s BTK inhibitors business to US firm Loxo for US$40mln.

It was confirmed last week that FRP had filed their final report in court and with the Registrar of Companies, bringing the administration to a close.

Chairman takes over the reins

Shares are set to resume trading at midday on Monday, although investors will now be backing a firm headed up by Iain Ross who has moved from non-executive to executive chairman.

READ: Biotech firm Redx Pharma comes out of administration

Ross has replaced Neil Murray who Redx confirmed has stepped down as both chief executive and as a director of the company.

Elsewhere in the boardroom, Peter Presland has joined as a non-executive director and chair of audit committee, replacing long-standing NED Norman Molyneux.

Two development programmes, five research programmes

Redx also unveiled its strategy going forward, which will see it focus on its lead cancer asset (RXC004) and fibrosis candidate (Pan-ROCK).

RXC004, a so-called 'porcupine inhibitor' (more on that below), is set to enter the clinic in the first quarter of 2018 with results from the phase Ia trial due at some point in the second half of that year.

READ: Redx gets UK go-ahead for first clinical trial of cancer treatment

Pan-ROCK, which specifically targets inflammatory bowel disease-related fibrosis, isn’t quite as far down the road yet but Redx reckons the potential market is around 3mln patients.

Alongside those two development programmes Redx is focusing on a further five earlier-phase research projects.

Given July’s BTK inhibitors sale, Redx has £13.6mln of cash in the bank which should last it into early 2019 and allow the company to “pass through a number of significant milestones”.

Boss “delighted” with stronger management team

“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business,” said executive chairman Ross.

“The strong research base has yielded a pipeline that is now focused on developing first or best in class drugs to validated targets in cancer and fibrosis where there remain significant unmet medical needs.

“We look forward to entering the clinic with our lead cancer compound in the first quarter of 2018 having recently received the necessary approvals for our trial design.”

He added: “Our aim is to progress our pipeline candidates, where warranted, to clinical proof of concept in order to build significant shareholder value.”

Porcupine inhibitors: Animal rescue?

Porcupine inhibitors are a new and potentially breakthrough method of fighting cancer.

They work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness.

The thinking goes that if you kill the stem cells, you have a chance of eradicating the disease completely.

There is a growing bank of research that has found they may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1, which lower or break cancer’s defence against the body’s immune system.

That’s why Redx announced recently that the upcoming trial of its RXC004 Porcupine inhibitor will assess the drug in combination with a checkpoint inhibitor as well as deploying it as a single treatment to tackle cancer.

So Redx has previously said it will build in a “combination arm” to next year’s study, “reflecting our belief in the validity of this approach”.

As it stands, Swiss pharmaceutical giant Roche is the only drug major with a Porcupine inhibitor in the clinic.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use